Derbend Asset Management Novo Cure LTD Transaction History

Derbend Asset Management

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 21, 2022	SELL	$56.6 - $89.9 $266,812 - $423,788	-4,714 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$75.08 - $121.99 $67,121 - $109,059	-894 Reduced 15.94%	4,714 $354,000
Q3 2021 Nov 15, 2021	SELL	$116.17 - $194.55 $21,026 - $35,213	-181 Reduced 3.13%	5,608 $651,000
Q2 2021 Jul 30, 2021	BUY	$130.4 - $225.58 $754,885 - $1.31 Million	5,789 New	5,789 $1.28 Million

262

77M

1.17M

318K

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.86B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

Get notified when there are updates to the investment portfolio of Derbend Asset Management, based on Form 13F filings with the SEC.

Stay updated on Derbend Asset Management with notifications on news.